Pharma’s $500B patent problem will come in waves — not as a cliff

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 12 Oct, 13:16 UTC

Merck is the most vulnerable to generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and others will also grapple with patent losses in the years to come.

science

Sources

• T2Pharma’s $500B patent problem will come in waves — not as a cliffBioPharma Dive / Healthcare Dive / MedTech Dive12 Oct, 13:16